Although cyclophosphamide has been previously shown to have multiple effects on the immune system [15], it was important to identify the minimum dose of CY that would allow us to observe its effects on immune cells without depletion of CD8+ T cells, which are central to the anti-tumor activities of SD-101 [5]. Here, CD8A is linked to neoplasm.